Connect with us

Press Release

Candel Therapeutics (NASDAQ: CADL) Lead Candidate CAN-2409 Combats Lung, Pancreatic And Prostate Cancers With Fast Track Designation For Three Cancers

Published

2 years ago

on

–News Direct–

By Jeremy Golden, Benzinga

Immunotherapy has transformed the way cancer is treated, but just 20% to 40% of patients typically respond to FDA-approved immune checkpoint inhibitor (ICI) treatments.

Poor ICI treatment response has been linked to the tumors ability to disguise antigen presentation and generate an immunosuppressive microenvironment. In addition, most conventional immunotherapies are not designed to educate the patients immune system on how to recognize a variety of tumor antigens and neoantigens.

Amid this landscape, a clinical-stage biopharmaceutical company has developed a new multimodal biological approach that leverages the ability of viral gene constructs to activate cancer-killing mechanisms, exposing multiple tumor antigens to the immune system, resulting in vaccination against the tumor while inhibiting the immunosuppressive tumor microenvironment.

Candel Therapeutics, Inc. (NASDAQ: CADL) is developing a product candidate that is being studied in lung, pancreatic and prostate cancers. Candels most advanced viral immunotherapy candidate, CAN-2409, is an investigational off-the-shelf replication-defective adenovirus designed to induce an individualized, systemic immune response against the patients own tumor.

Part of the companys adenovirus platform, CAN-2409 is injected directly into the tumor or target tissue using a localized injection, akin to the standard approach for vaccination.

CAN-2409's adenoviral construct serves as a vector to transport the HSV-thymidine kinase gene into tumor cells at the site of injection. These tumor cells can then express HSV-thymidine kinase, which converts generic, FDA-approved anti-herpes drugs such as ganciclovir, acyclovir and valacyclovir into a toxic nucleotide analog that blocks DNA synthesis in dividing cells.

Cancer cells exposed to the toxic nucleotide analog in the tumor microenvironment have been observed to undergo immunogenic cell death. Simultaneously, the adenoviral serotype 5 capsid protein elicits a strong pro-inflammatory signal in the tumor microenvironment, creating the optimal conditions to induce a specific CD8+ T cell-mediated response against the injected tumor and uninjected distant metastases for broad and systemic anti-tumor activity.

CAN-2409 is currently being studied in an open-label, phase 2 clinical trial in non-small cell lung cancer (NSCLC) and in randomized, controlled, blinded phase 2b and phase 3 clinical trials in prostate cancer. The company has recently released very encouraging data for CAN-2409s ability to improve overall survival in non-metastatic pancreatic cancer, with topline overall survival data in non-small cell lung cancer planned for this quarter (Q2 2024) and results from the prostate clinical trials later this year (Q4 2024).

When it comes to NSCLC, the company previously presented data from the phase 2 clinical trial in which patients received two administrations of CAN-2409 plus prodrug. Those patients demonstrated the following:

1) Increased infiltration of CD8+ cytotoxic T cells in the tumor microenvironment, systemic expansion of effector T cells and increased soluble granzyme B levels in peripheral blood;

2) Favorable changes in the trajectory of tumor progression;

3) Decreased tumor size of target lesions in most patients; and

4) Reduced size of uninjected tumor lesions.

The CAN-2409 immunotherapy antitumor strategy aims to increase the number of long survivors beyond 10 to 13 months.

As previous work has shown that progressive disease could be converted into stable disease in most patients with non-small cell lung cancer after CAN-2409 treatment, the hypothesis is that this will translate into improved survival.

When it comes to pancreatic cancer, the company reported notable improvements in patients with borderline resectable pancreatic ductal adenocarcinoma (PDAC) after experimental treatment with CAN-2409. The estimated overall survival rate was 71.4% at 24 months in CAN-2409-treated patients versus only 16.7% in the control arm after chemoradiation.

In 2023, CAN-2409 received Fast Track Designation for both non-small cell lung cancer and pancreatic cancer, a validation from the FDA on its potential. CAN-2409 plus valacyclovir in combination with continued PD-1/PD-L1 agents is being evaluated in an ongoing, open-label phase 2 clinical trial in patients with late-stage NSCLC and an inadequate response to anti-PD(L)-1 therapy. In 2024, CAN-2409 also received Orphan Drug Designation from the FDA for CAN-2409 in borderline resectable pancreatic cancer.

In the upcoming year, Candel plans to announce data readouts for the following:

1) Phase 2 topline overall survival (OS) data for CAN-2409 in NSCLC, expected in Q2 2024;

2) Phase 2 topline data for CAN-2409 in low-to-intermediate-risk, localized, non-metastatic prostate cancer, expected in Q4 2024;

3) Phase 3 topline data for CAN-2409 in localized intermediate/high-risk prostate cancer, expected in Q4 2024.

Featured photo by National Cancer Institute on Unsplash.

Candel is a clinical stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is currently in ongoing clinical trials in non-small cell lung cancer (NSCLC) (phase 2), borderline resectable pancreatic cancer (phase 2), and localized, non-metastatic prostate cancer (phase 2 and phase 3). CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing investigator-sponsored phase 1 clinical trial in recurrent high-grade glioma (HGG). Finally, Candels enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.

This article includes certain disclosures that contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of development programs, including the timing and availability of additional data, key data readout milestones, including CAN-3110 in HGG; expectations regarding the potential benefits conferred by Fast Track Designation; expectations regarding the therapeutic benefit of its programs, including the potential for its programs to extend patient survival; and expectations regarding cash runway and expenditures. The words may, will, could, would, should, expect, plan, anticipate, intend, believe, estimate, predict, project, potential, continue, target and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on managements current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Companys programs; that final data from our pre-clinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Companys ability to efficiently discover and develop product candidates; the Companys ability to obtain and maintain regulatory approval of product candidates; the Companys ability to maintain its intellectual property; the implementation of the Companys business model, and strategic plans for the Companys business and product candidates, and other risks identified in the Companys SEC filings, including the Companys most recent Quarterly Report on Form 10-Q filed with the SEC, and subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Companys views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.

Contact Details

Aljanae Reynolds

+1 617-916-5445

areynolds@wheelhouselsa.com

Company Website

https://www.candeltx.com/

View source version on newsdirect.com: https://newsdirect.com/news/candel-therapeutics-nasdaq-cadl-lead-candidate-can-2409-combats-lung-pancreatic-and-prostate-cancers-with-fast-track-designation-for-three-cancers-458506267

Candel Therapeutics

comtex tracking

COMTEX_453480918/2655/2024-06-07T08:28:02

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Related Topics:
Continue Reading

Press Release

BiFinance Lists EVOCARE-USDT and Launches Trading Competition with Exclusive Rewards

Published

26 minutes ago

on

March 19, 2026

By

BiFinance, a leading Web3 digital asset trading platform, has officially announced the listing of EVOCARE (EVOCARE) and the launch of a dedicated trading competition, offering users multiple participation opportunities and enhanced engagement.

EVOCARE Officially Listed on BiFinance

According to the official announcement, BiFinance has listed the EVOCARE USDT trading pair, with deposit and trading services opened on March 12, 2026.

EVOCARE represents an innovative Web3 healthcare initiative focused on building a digital therapy ecosystem. As The World Therapy Store, EvoCare aims to connect patients, therapists, and healthcare creators through a scalable and compliant infrastructure, integrating real-world medical services with blockchain technology and bringing real-world utility into the Web3 space.

The platform combines regulated healthcare services with Web3 utility infrastructure, creating a scalable global ecosystem for therapy, rehabilitation, and digital health services. EvoCare is designed to enable German-quality therapeutic care to be delivered anywhere in the world through a clinically supervised digital healthcare platform.

Official Website:

https://evocare.healthcare

The EVOCARE token serves as the core of the ecosystem, supporting:

Digital therapy service payments

Creator support mechanisms

Access to regulated healthcare solutions

By linking real healthcare demand with tokenized utility, EVOCARE creates a sustainable and value-driven ecosystem backed by real-world applications.

Trading Competition Now Live with Trading Competition Details

To celebrate the listing, BiFinance has launched the EVOCARE Trading Competition, allowing users to trade EVOCARE USDT and compete for benefits.

Participants can:

Trade EVOCARE USDT to climb leaderboard rankings

Receive benefits based on trading performance

Unlock additional advantages such as trading additional benefits

The competition is designed to encourage active participation while benefiting both new and experienced traders.

Expanding the RWA and Utility-Driven Ecosystem

The listing of EVOCARE reflects BiFinance’s continued commitment to supporting projects with real-world utility and strong growth potential. By bridging traditional sectors such as healthcare with blockchain infrastructure, BiFinance further strengthens its “virtual + real” ecosystem strategy.

Through ongoing listings, trading campaigns, and ecosystem collaboration, BiFinance aims to provide users with:

High-quality asset access

Enhanced trading opportunities

A more diversified and utility-driven Web3 experience

About BiFinance

BiFinance is a Web3 digital asset trading platform focused on the integration of Real-World Assets (RWA) and blockchain technology. The platform is committed to building a secure, compliant, and scalable financial ecosystem, connecting traditional finance with the decentralized world.

With a growing global presence and continuous innovation in both product and ecosystem design, BiFinance is accelerating the evolution of digital finance through its “Bi+Finance” model.

Media Contact

Organization: BiFinance

Contact Person: Ben

Website: https://www.bifinance.com

Email:
listing@BiFinance.com

Country:Canada

Release id:42777

The post BiFinance Lists EVOCARE-USDT and Launches Trading Competition with Exclusive Rewards appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Advanced Strapless Goalkeeper Gloves Officially Released, Available at Just Keepers

Published

26 minutes ago

on

March 19, 2026

By

Hinckley, Leicestershire, United Kingdom, 19th Mar 2026 – Just Keepers has added advanced strapless goalkeeper gloves to its selection, reflecting growing interest in strap-free designs within the goalkeeping community.

The Goalkeeper gloves feature a slip-on construction, removing the need for a traditional wrist strap and offering a clean, streamlined fit. This design approach aligns with the preferences of goalkeepers seeking simplicity and a more natural feel during play.

With a reduced structure around the wrist, the gloves are suited for both training and match environments, supporting comfort and ease of movement on the pitch.

Strapless gloves are becoming an increasingly talked-about option among goalkeepers. Their inclusion reflects the shift towards more simplified designs in modern goalkeeping gear.

The addition highlights ongoing changes in goalkeeper equipment, as players continue to explore new styles and fits that suit their individual preferences.

For more information
https://www.just-keepers.com/goalkeeper-gloves/goalie-gloves/reusch-gk-gloves/

About Just Keepers Ltd

Just Keepers is a dedicated retailer specialising exclusively in goalkeeping equipment, offering a curated selection tailored to the specific needs of the position. Its range covers goalkeeper gloves, technical clothing, and essential accessories suited for both training sessions and competitive matches. Catering to players at every level, from beginners to professionals, the company focuses on purpose-built gear, durability, and consistent performance across its lineup.

Media Contact

Organization: Just Keepers Ltd

Contact Person: Just Keepers Ltd

Website: https://www.just-keepers.com/

Email: Send Email

City: Hinckley, Leicestershire

Country:United Kingdom

Release id:42820

The post Advanced Strapless Goalkeeper Gloves Officially Released, Available at Just Keepers appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Macmillan Lawyers and Advisors Supports Brisbane Businesses with Strategic Legal Advisory Services

Published

56 minutes ago

on

March 19, 2026

By

Australia, 19th Mar 2026 – Macmillan Lawyers and Advisors, a respected Brisbane-based commercial law firm, has strengthened its strategic legal advisory services to support businesses across Brisbane navigating complex commercial and regulatory environments. The firm provides guidance to organisations at various stages of development, including business establishment, dispute resolution, and financial restructuring.

Operating from Level 38, 71 Eagle Street in Brisbane City, Macmillan Lawyers and Advisors works with businesses ranging from emerging enterprises to established companies. Legal advice is designed to assist organisations managing contractual obligations, regulatory compliance requirements, and operational challenges.

Across Australia, businesses continue to face evolving regulations, economic pressures, and changing market conditions. These developments have increased demand for legal advisory services that help organisations identify risks and address complex legal matters early.

Macmillan Lawyers and Advisors provides services across several areas of commercial law, including contract law, commercial disputes, intellectual property protection, bankruptcy and insolvency matters, liquidation processes, and turnaround strategies. Legal support focuses on helping businesses understand their legal responsibilities while developing practical approaches to commercial challenges.

Kyle Macmillan, Principal of Macmillan Lawyers and Advisors, said strategic legal guidance plays an important role for businesses operating in a changing commercial environment.

“Businesses across Brisbane are navigating an environment that requires careful legal and strategic planning,” said Macmillan. “Access to experienced legal advisory services assists organisations in addressing disputes, contractual obligations, and financial restructuring matters in a structured and informed manner.”

The firm provides legal support throughout different stages of the corporate lifecycle. Early-stage assistance includes advice on company establishment, governance structures, shareholder agreements, and intellectual property protection. For established organisations, services often involve dispute resolution, contract negotiation, and regulatory compliance guidance.

Macmillan Lawyers and Advisors also advises businesses experiencing financial difficulty or operational restructuring. Legal support in insolvency, bankruptcy, and turnaround planning helps organisations understand available legal options and obligations during periods of financial stress.

Industry professionals note that early legal guidance can assist businesses in managing disputes and addressing potential financial challenges before problems escalate. Strategic legal planning is increasingly viewed as an important component of responsible corporate governance and long-term stability.

Macmillan noted that ongoing changes within regulatory environments highlight the importance of consistent legal insight.

“Changes within regulatory environments and market conditions highlight the importance of ongoing legal insight for businesses,” Macmillan said. “Strategic advisory services will continue to support organisations as they adapt to future challenges while maintaining compliance and operational resilience.”

For media enquiries, Macmillan Lawyers and Advisors, a business lawyer Brisbane firm providing commercial legal services to organisations across Queensland, can be contacted at Level 38, 71 Eagle Street, Brisbane City QLD 4000. Enquiries may be directed by phone on (07) 3518 8030 or via email at admin@macmillan.law.

Media Contact

Organization: Macmillan Lawyers and Advisors

Contact Person: Kyle Macmillan

Website: https://macmillan.law/

Email: Send Email

Contact Number: +61735188030

Address:Level 38/71 Eagle St

Address 2: Brisbane City QLD 4000

Country:Australia

Release id:42813

The post Macmillan Lawyers and Advisors Supports Brisbane Businesses with Strategic Legal Advisory Services appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST

Like Us
Follow Us
Subscribe Us
Follow Us